166975-76-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Piperidinoethoxy)benzoic acid hydrochloride is used as a pharmaceutical intermediate for the synthesis of various drugs, contributing to the development of medications that target specific biological pathways.
Used in Research and Development:
In the pharmaceutical industry, 4-(2-Piperidinoethoxy)benzoic acid hydrochloride is utilized in research and development to explore its potential applications in creating new pharmaceutical products and chemical compounds, enhancing the therapeutic outcomes of existing medications, and addressing unmet medical needs.

InChI:InChI=1/C14H19NO3.ClH/c16-14(17)12-4-6-13(7-5-12)18-11-10-15-8-2-1-3-9-15;/h4-7H,1-3,8-11H2,(H,16,17);1H

Upstream product

• 84449-80-9 4-(2-piperidin-1-ylethoxy)benzoic acid hydrochloride 
• 89407-98-7 4-(2-(piperidin-1-yl)-ethoxy)benzoic acid 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 93148-78-8 ethyl 4-(2-Piperidinylethoxy)benzoate 
• 2008-75-5 N-chloroethylpiperidine hydrochloride 
• 3040-44-6 1-piperidinoethanol 
• 89407-97-6 4-[2-(N-piperidine)-ethoxy]benzoic acid methyl ester 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 84541-36-6 [2-(4-methoxyphenyl)-6-methoxybenzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride 
• 84449-85-4 <6-<(methylsulfonyl)oxy>-2-<4-<(methylsulfonyl)oxy>phenyl>benzothien-3-yl><4-<2-(1-pyrrolidinyl)ethoxy>phenyl>methanone hydrochloride 
• 476304-42-4 [6-methoxy-2-(4-methoxy-phenyl)-3,4-dihydro-2H-quinolin-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 476304-43-5 (6-methoxy-2-phenyl-3,4-dihydro-2H-quinolin-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 165742-76-7 [2-dimethylamino-6-methoxybenzothien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone 
• 648905-80-0 (2,6-dimethoxynaphthalen-1-yl)-[4-(2-piperidin-1-ylethoxy)phenyl]methanone 
• 649724-98-1 (2-hydroxy-6-methoxy-naphthalen-1-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 166975-19-5 N-{2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-benzo[b]thiophen-6-yl}-acetamide 
• 166975-25-3 (2-Benzothiazol-6-yl-6-hydroxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone 
• 271-89-6 1-benzofurane 
• 1319210-03-1 N-(2-acetylphenyl)-4-(2-piperidin-1-ylethoxy)benzamide 
• 1319210-09-7 2-[4-(2-piperidin-1-ylethoxy)phenyl]quinolin-4-ol 
• 1260244-32-3 N,N-diethyl-2-({2-[4-(2-piperidin-1-ylethoxy)phenyl]-quinolin-4-yl}oxy)ethanamine 

Relevant academic research and scientific papers

A novel salicylic acid derivatives preparation method and its application in treating the tumor

The invention belongs to the field of biological medicine, and particularly provides a novel salicylic acid derivatives and application in treating the tumor. We use the chemical synthetic method has been a series of novel salicylic acid derivatives of the compound. We found that the biological activity of the compounds to identify breast cancer, lung cancer, leukemia and other various cell strain has obvious antagonistic effect, we study found that anti-tumor mechanism of the class of compounds STAT3 cell signal transduction have prominent inhibit function, the display of these compounds for the treatment of STAT3 signal conduction abnormality types of cancer has a great significance.

DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases

A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA

Evolution from a natural flavones nucleus to obtain 2-(4-propoxyphenyl) quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump

Overexpression of efflux pumps is an important mechanism by which bacteria evade the effects of substrate antimicrobial agents. Inhibition of such pumps is a promising strategy to circumvent this resistance mechanism. NorA is a Staphylococcus aureus efflux pump that confers reduced susceptibility to many structurally unrelated agents, including fluoroquinolones, resulting in a multidrug resistant phenotype. In this work, a series of 2-phenyl-4(1H)- quinolone and 2-phenyl-4-hydroxyquinoline derivatives, obtained by modifying the flavone nucleus of known efflux pump inhibitors (EPIs), were synthesized in an effort to identify more potent S. aureus NorA EPIs. The 2-phenyl-4- hydroxyquinoline derivatives 28f and 29f display potent EPI activity against SA-1199B, a strain that overexpresses norA, in an ethidium bromide efflux inhibition assay. The same compounds, in combination with ciprofloxacin, were able to completely restore its antibacterial activity against both S. aureus SA-K2378 and SA-1199B, norA-overexpressing strains.

NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS

The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.

NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS

The present invention is directed to novel tetracyclic heteroatom containing derivatives of formula (II), pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and proces

Synthesis and binding affinities of fluoroalkylated raloxifenes

Three fluoroalkylated derivatives (1-3) of the selective estrogen receptor modulator (SERM), raloxifene, have been synthesized. The key step in the synthesis is the C-C bond formation of benzo[b]thiophene and a substituted phenyl group (ring C) using a Stille reaction. The in vitro binding affinities of the substituted raloxifenes 1-3 are 45, 60, 89%, respectively, relative to the affinity of estradiol, which is higher than the affinity of raloxifene itself (25%). When labeled with the positron-emitting radionuclide, these compounds might be useful as PET imaging agents for estrogen receptor-positive breast tumors.

Process for preparing 3-(4-aminoethoxy-benzoyl) benzo B!-thiophenes

The invention provides a process for preparing 6-alkoxy-3-(4-alkoxyphenyl)benzo B!thiophenes in good yield on a manufacturing scale without generating a thick, potentially yield-reducing, paste. The invention also provides methods for converting a-(-alkoxyphenylthio)-4-alkoxyacetophenones into 6-hydroxy-2-(4-hydroxyphenyl)-3- 4-(2-aminoethoxy)benzoyl!benzo B!thiophenes via acylation of a dialkoxy benzo B!thiophene. Each of these preparations relies on an intramolecular cyclization of a dialkoxy acetophenone derivative to yield a benzo B!thiophene without generating a thick paste that lowers overall yields on a manufacturing scale.

Antiestrogens. 2. Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzothiophene Derivatives Leading to thien-3-yl>phenyl>methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with On...

In an effort to prepare nonsteroidal antiestrogens demonstrating greater antagonism and less intrinsic estrogenicity than those currently available, a series of 3-aroyl-2-arylbenzothiophene derivatives was synthesized.These compounds were prepared by Friedel-Crafts aroylation of appropriate O-protected 2-arylbenzothiophene nuclei with basic side-chain-bearing benzoyl chlorides followed by removal of the protective groups to provide the desired compounds containing both hydroxyl and basic side-chain functionality.A particularly useful method for the cleavage of aryl methoxy ethers without removal of (dialkylamino)ethoxy side chain functionality elsewhere in the molecule was found to be AlCl3/EtSH.The benzothiophene derivatives were tested for their ability to inhibit the growth-stimulating action of estradiol on the immature rat uterus.Seemingly minor changes in the side-chain amine moiety were found to have profound effects on the ability of the compounds to antagonize estradiol.Analogues having basic side chains containing cyclic (pyrrolidine, piperidine, and hexamethyleneamine) moieties were found to have less intrinsic estrogenicity and to antagonize estradiol action more completely than their noncyclic counterparts.The most effective antiestrogen in the series, compound 44, thien-3-yl>phenyl>methanone, elicited a modest uterotropic activity that did not increase with increasing dose.In antagonism of estradiol, 44 exhibited a degree of inhibition surpassing that of tamoxifen at any dose tested.The new benzothiophene antiestrogen was also shown to have high affinity for rat uterine cycloplasmic estrogen receptor and to be an inhibitor of the growth of DMBA-induced rat mammary tumors.

Antiestrogenic and antiandrugenic benzothiophenes

6-Hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, its ethers and esters, and the physiologically acceptable acid addition salts thereof, are valuable antiestrogens and antiendrogens.

Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes

The use of particularly advantageous protecting groups for the hydroxy groups of 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophenes provides a high-yielding process for the preparation of such compounds having a 4-(2-aminoethoxy)benzoyl 3-group.